84182-46-7

Usage

Uses

Used in Organic Synthesis:
3-(Benzyloxy)cyclobutane-1,1-dicarboxylic acid is used as a key intermediate in the synthesis of complex organic molecules. Its benzyl ether group and cyclobutane core provide unique reactivity and structural features that facilitate the formation of diverse heterocyclic compounds and other organic products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-(Benzyloxy)cyclobutane-1,1-dicarboxylic acid is utilized as a starting material for the development of novel drug candidates. Its unique structural features and reactivity enable the design and synthesis of biologically active molecules with potential therapeutic applications.
Used in Drug Design and Development:
3-(Benzyloxy)cyclobutane-1,1-dicarboxylic acid is employed as a building block in drug design and development. Its cyclobutane core and benzyl ether group offer opportunities for the creation of new chemical entities with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-(Benzyloxy)cyclobutane-1,1-dicarboxylic acid serves as a valuable chemical for the advancement of drug discovery and optimization. Its unique structural features and reactivity contribute to the development of innovative therapeutic agents with potential applications in various disease areas.

InChI:InChI=1/C13H14O5/c14-11(15)13(12(16)17)6-10(7-13)18-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,15)(H,16,17)

Upstream product

• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 
• 100-39-0 benzyl bromide 
• 54307-67-4 1-bromo-2-benzyloxy-3-chloropropane 

Downstream Products

• 4958-02-5 3-(benzyloxy)cyclobutane-1-carboxylic acid 
• 132332-58-2 3β-(6-amino-9H-purin-9-yl)cyclobutane-1α-methanol 
• 125962-36-9 9-adenine 
• 1124175-26-3 3-(benzyloxy)cyclobutane-1-carbonyl chloride 
• 156865-32-6 3-(benzyloxy)cyclobutane-1-methanol 
• 128041-57-6 3α-(benzyloxy)cyclobutane-1β-methanol 
• 141352-64-9 3α-(benzyloxy)cyclobutane-1α-methanol 
• 141352-63-8 1α-benzyloxy-3β-carbethoxy-cyclobutane 
• 141352-62-7 ethyl 3α-(benzyloxy)cyclobutane-1α-carboxylate 
• 141352-68-3 3β-<((tert-butyl)diphenylsilyloxy)methyl>cyclobutane-1α-ol 
• 141352-67-2 3α-<((tert-butyl)diphenylsilyloxy)methyl>cyclobutane-1α-ol 
• 141352-66-1 1α-(benzyloxy)-3β-<((tert-butyl)diphenylsilyloxy)methyl>cyclobutane 
• 141352-65-0 1α-(benzyloxy)-3α<((tert-butyl)diphenylsilyloxy)methyl>cyclobutane 
• 141352-71-8 9-<3α-(((tert-butyl)diphenylsilyloxy)methyl)cyclobut-1β-yl>-9H-purin-6-amine 

Relevant academic research and scientific papers

BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS

Heteroaryloxycarbocyclyl compounds of formula (I), and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive -compulsive disorder, and the like. Formula (I)

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

NOVEL INTERMEDIATES AND THEIR USE

The invention is directed to novel acyloxy imidazole intermediates useful for making certain C- 14 oxycarbonyl carbamate pleuromutilin derivatives. The invention is further directed to a process for making such acyloxy imidazole intermediates and to a pro

NEW PLEUROMUTILIN DERIVATIVE AND ITS USE

The invention is directed to the L-tartrate salt of trans-3-aminocyclobutyl (lS,2R,3S,4S:,6R,7R,8R-,14R)-4-ethenyl-3-hydroxy-2,4,7, 14-tetramethyl-9- oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is useful for the treatment of a variety of diseases and conditions, such as respiratory tract and skin and skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA.